Press releases

14 December, 202319 February, 2024

Abliva Receives Orphan Designation from the European Commission for its Drug Candidate NV354

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the European Commission has gr ...

17 November, 202319 February, 2024

Regulatory

Abliva AB Interim Report January – September 2023

KL1333 Received FDA Fast Track Designation | The FALCON Study Reached an Important Milestone

14 November, 202319 February, 2024

Regulatory

Abliva and Owl Therapeutics enter into licensing and collaboration agreement for NeuroSTAT® in Traumatic Brain Injury

Abliva AB (‘Abliva’ or the ‘Company’) and US-based Owl Therapeutics today announced the signing of a licensing and collaboration agreement for Abliva’s NeuroSTAT® for the treatment of moderate to seve ...

11 October, 202319 February, 2024

Abliva Achieves Important Milestone in the Ongoing FALCON Study

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company has now included the t ...

18 September, 2023

Abliva to Participate in World Mitochondrial Disease Week 2023

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company will participate in W ...

4 September, 2023

Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation

18 August, 2023

Regulatory

Abliva AB Interim Report January – June 2023

The first patient was dosed in the FALCON study ⎮ Orphan Drug Designation for NV354

29 June, 2023

Abliva presents at UMDF Mitochondrial Medicine 2023

28 June, 2023

Abliva announces first patient dosed in the FALCON study

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the first patient has been dosed ...

12 June, 2023

Abliva presents scientific data at international conference on mitochondrial medicine

23 May, 2023

Regulatory

Abliva AB Interim Report January – March 2023

Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354

5 May, 2023

Regulatory

Resolutions from Annual General Meeting in Abliva AB (publ) on May 5, 2023

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 5, 2023, held its Annual General Meeting (“AGM”). A summary of the resolution follows.